Open AccessBrief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
Author(s) -
Josep M Llibre,
Luis Fernando López Cortés,
Alicia Aylott,
Brian Wynne,
James L. Matthews,
Rodica Van SolingenRistea,
Kati Vandermeulen,
Jean van Wyk,
Lesley Kahl
Publication year - 2022
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000003019
Subject(s) - rilpivirine , dolutegravir , medicine , regimen , pharmacology , human immunodeficiency virus (hiv) , virology , viral load , antiretroviral therapy
Switching to the 2-drug regimen dolutegravir + rilpivirine demonstrated noninferiority vs continuing a 3-drug or 4-drug current antiretroviral regimen (CAR) at week 48 and maintained high levels of virologic suppression to week 148 in the SWORD studies. We report inflammation and atherogenesis biomarkers postswitch to dolutegravir + rilpivirine.